# Clinical Trial to Evaluate Pharmacokinetics,Safety and Immunogenicity of Single Injection of CDP1 to Healthy Volunteers Compared to Erbitux

> **NCT03881787** · PHASE1 · UNKNOWN · sponsor: **Dragonboat Biopharmaceutical Company Limited** · enrollment: 84 (estimated)

## Conditions studied

- Healthy Volunteers

## Interventions

- **DRUG:** anti-EGFR monoclonal antibody
- **DRUG:** Cetuximab injection

## Key facts

- **NCT ID:** NCT03881787
- **Lead sponsor:** Dragonboat Biopharmaceutical Company Limited
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2019-02-27
- **Primary completion:** 2019-10-30
- **Final completion:** 2019-12-30
- **Target enrollment:** 84 (ESTIMATED)
- **Last updated:** 2019-03-20

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03881787

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03881787, "Clinical Trial to Evaluate Pharmacokinetics,Safety and Immunogenicity of Single Injection of CDP1 to Healthy Volunteers Compared to Erbitux". Retrieved via AI Analytics 2026-07-08 from https://api.ai-analytics.org/clinical/NCT03881787. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*